CYTOTRON
 
  Shr�is-Scalene
Cytotron
Arthritis
Cancer                            Multiple Sclerosis
Clinical Studies
Scientific Research
Inventor                         The Team
FAQ                              
In The News
 
 
 

Shreis-Scalene Sciences
11516 Darnestown Rd. Gaithersburg,MD 20878
Tel : (001)301-926-0566
Fax : (001)301-926-2925
email : Shr�is.com

 

Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, progressive neurologic disease characterized by scattered demyelination of nerve fibers in the brain and spinal cord. Fatigue, vertigo, spasticity and muscle spasms, psychological problems, urinary dysfunction, sexual problems ,tremors and incoordination, pain and cognitive problems are some of the associated effect of MS. Within 40 years of its first depiction, the clinical and pathological details of multiple sclerosis had been adequately characterised. Over the past 120 years, ideas have consolidated on the cause and mechanisms of inflammatory demyelination and axonopathy. In the past 10 years, therapies have emerged that modestly affect the course of the illness. Current research is increasingly seen as coherent and focused on the hot topics that need to be solved to limit, repair, and prevent the damage caused by multiple sclerosis.

The use of the Cytotron� in the treatment of Multiple Sclerosis has shown extremely promising results. Based on these preliminary results from patients treated with the Cytotron�, S-CARD, Bangalore has registered a trial for Multiple Sclerosis with the NIH clinicaltrials.gov (NCT01220830). The purpose of the study is to evaluate the efficacy of RFQMR therapy in remyelination in cases of Multiple sclerosis. The evaluation will be done based on MRI findings, by clinical/ neurological examination and by assessment of quality of life before and after completion of therapy. 
Shreis plans to repeat a similar trial here in the US.
Shreis has already commenced work in Canada for a study of MS patients and to follow it with a clinical trial as per Health Canada regulations.

SHREIS HAS THE MARKETING RIGHTS ALSO FOR MULTIPLE SCLEROSIS FOR NORTH AND SOUTH AMERICAS AND THE CARIBBEAN INCLUDING MEXICO

 Clinical Trial registered with NIH ClinicalTrials.gov Identifier: NCT01220830

 

 

 

 

In the NEWS 

RFQMR



Haemoseis-256

 

Engineering Solutions to Human Problems